 Aprea Therapeutics, Inc. APRE, a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced the oral presentation of updated data from its French Phase 1b2 clinical trial at the 25th European Hematology Association Annual Meeting EHA. The trial is evaluating the safety and efficacy of APR-246 eprenetapopt in combination with azacitidine AZA for the treatment of TP53 mutant myelodysplastic syndromes MDS and acute myeloid leukemia AML. 